Mustang Bio Company Leadership
| MBIO Stock | USD 0.19 0 2.11% |
Mustang Bio employs about 80 people. The company is managed by 15 executives with a total tenure of roughly 187 years, averaging almost 12.0 years of service per executive, having 5.33 employees per reported executive. Analysis of Mustang Bio's management performance can provide insight into the firm performance.
Mustang Bio's Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2023-03-18 | Manuel Md Litchman | Acquired 333 @ 11.1 | View | ||
| 2021-12-14 | Brian Achenbach | Disposed 291 @ 27.45 | View |
Monitoring Mustang Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mustang |
Mustang Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.9652) % which means that it has lost $0.9652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.9131) %, meaning that it created substantial loss on money invested by shareholders. Mustang Bio's management efficiency ratios could be used to measure how well Mustang Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to grow to -2.76. In addition to that, Return On Capital Employed is likely to grow to -20.32. At this time, Mustang Bio's Net Tangible Assets are very stable compared to the past year. As of the 11th of December 2024, Non Current Assets Total is likely to grow to about 8.8 M, while Total Assets are likely to drop about 16.9 M.As of the 11th of December 2024, Common Stock Shares Outstanding is likely to drop to about 5.3 M. In addition to that, Net Loss is likely to grow to about (66.3 M)
Mustang Bio Workforce Comparison
Mustang Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,613. Mustang Bio holds roughly 80.0 in number of employees claiming about 5% of equities under Health Care industry.
Mustang Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mustang Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mustang Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mustang Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Litchman Manuel Md few days ago Acquisition by Litchman Manuel Md of 153846 shares of Mustang Bio at 3.25 subject to Rule 16b-3 | ||
Jin David over a month ago Insider Trading | ||
Rosenwald Lindsay A Md over a month ago Disposition of tradable shares by Rosenwald Lindsay A Md of Mustang Bio subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over two months ago Acquisition by Rosenwald Lindsay A Md of 5000 shares of Mustang Bio at 0.5164 subject to Rule 16b-3 | ||
Litchman Manuel Md over two months ago Acquisition by Litchman Manuel Md of 86206 shares of Mustang Bio at 2.91 subject to Rule 16b-3 | ||
Chill Adam J. over three months ago Acquisition by Chill Adam J. of 2000 shares of Mustang Bio at 5.34 subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over three months ago Acquisition by Rosenwald Lindsay A Md of 1170 shares of Mustang Bio at 2.58 subject to Rule 16b-3 | ||
Litchman Manuel Md over three months ago Acquisition by Litchman Manuel Md of 8000 shares of Mustang Bio at 3.3506 subject to Rule 16b-3 |
Mustang Bio Notable Stakeholders
A Mustang Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mustang Bio often face trade-offs trying to please all of them. Mustang Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mustang Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Manuel MD | CEO, President | Profile | |
| Michael Esq | Executive Chairman | Profile | |
| Lynn MS | VP Affairs | Profile | |
| MS MBA | VP Leadership | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Richard MS | Head Development | Profile | |
| Matthew JD | VP Counsel | Profile | |
| Bruce MD | Senior Development | Profile | |
| Peter Carney | Controller Officer | Profile | |
| James Murphy | Interim Officer | Profile | |
| Robyn Hunter | Co Sec | Profile | |
| Scott MBA | Ex Management | Profile | |
| Knut Niss | Chief Officer | Profile | |
| Greg MS | Chief Officer | Profile | |
| Debra SPHR | Senior Resources | Profile |
About Mustang Bio Management Performance
The success or failure of an entity such as Mustang Bio often depends on how effective the management is. Mustang Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mustang management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mustang management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.91) | (2.76) | |
| Return On Capital Employed | (21.39) | (20.32) | |
| Return On Assets | (2.91) | (2.76) | |
| Return On Equity | (419.53) | (398.55) |
Mustang Bio Workforce Analysis
Traditionally, organizations such as Mustang Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mustang Bio within its industry.Mustang Bio Manpower Efficiency
Return on Mustang Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 645K | |
| Net Loss Per Executive | 3.4M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.33) | Revenue Per Share (0) | Return On Assets (0.97) | Return On Equity (11.91) |
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.